Vivelle-Dot vs. Bijuve
See how Vivelle-Dot and Bijuve compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Vivelle-Dot is a twice-weekly estrogen-only patch, while Bijuve is a once-daily capsule that already combines estrogen and progesterone in each dose.
Women with a uterus using Vivelle-Dot need a separate progestin prescription, but Bijuve already includes progesterone to protect the uterine lining.
Both carry boxed warnings for blood clots, stroke, dementia, and breast cancer, so either choice calls for a personal risk discussion with a doctor.
Vivelle-Dot vs. Bijuve Drug Summary
Vivelle-Dot
Vivelle-Dot is an estrogen-only hormone patch that delivers estradiol through the skin. It treats moderate to severe hot flashes and vaginal dryness from menopause, and can also treat low estrogen from ovarian failure or prevent bone loss after menopause. The patch is changed twice a week and comes in five strengths so a clinician can adjust the estrogen dose.
Bijuve
Bijuve is a combination hormone capsule that pairs estradiol with micronized progesterone in a single dose. It treats moderate to severe hot flashes from menopause in women who still have a uterus, where the built-in progesterone protects the uterine lining from unopposed estrogen. It is taken as one capsule by mouth once a day.
Vivelle-Dot vs. Bijuve Side Effects
Vivelle-Dot
Bijuve
Vivelle-Dot vs. Bijuve Dosage
Vivelle-Dot
Bijuve
| STAGE | DOSE | WHEN |
| Starting dose | 0.0375 mg/day patch | At the start |
| Maximum dose | 0.025-0.1 mg/day patch | If needed |
| Dose changes | 2 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg once daily | At the start |
| Maximum dose | 0.5 mg/100 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Vivelle-Dot
| STAGE | DOSE | WHEN |
| Starting dose | 0.0375 mg/day patch | At the start |
| Maximum dose | 0.025-0.1 mg/day patch | If needed |
| Dose changes | 2 increases | As tolerated |
Bijuve
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg once daily | At the start |
| Maximum dose | 0.5 mg/100 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Vivelle-Dot vs. Bijuve Indications
Vivelle-Dot
Vivelle-Dot is FDA-approved for moderate to severe hot flashes and vaginal dryness caused by menopause. It also treats low estrogen levels from ovarian failure or hypogonadism, and can prevent bone loss after menopause. Because it delivers estrogen alone, a separate progestin is usually needed for women who still have a uterus.
Moderate to severe hot flashes from menopause
Vaginal dryness and irritation from menopause
Low estrogen from ovarian failure or hypogonadism
Prevention of postmenopausal osteoporosis
Bijuve
Bijuve is FDA-approved specifically for moderate to severe hot flashes caused by menopause in women who still have a uterus. The progesterone in each capsule protects the uterine lining from the estrogen, so it is not approved for women without a uterus. It is also not approved to prevent heart disease, stroke, or dementia.
Moderate to severe hot flashes from menopause
For women who still have a uterus only
Progesterone included to protect the uterus
Not approved for women without a uterus
Vivelle-Dot vs. Bijuve Pros and Cons
Vivelle-Dot
Vivelle-Dot offers flexible dosing across five patch strengths and is one of the few estrogen products also approved to prevent bone loss. As an estrogen-only product, it needs to be paired with a separate progestin for anyone with a uterus, and generic pricing is far below the brand.
Pros
Five dose strengths allow fine-tuned titration
Also approved to prevent postmenopausal osteoporosis
Transdermal delivery may carry lower clot risk than oral estrogen
Cons
Requires a separate progestin prescription for women with a uterus
Patch can cause skin redness or irritation at the site
Brand-name supply has been inconsistent amid 2026 shortages
Must be changed and site-rotated twice a week
Bijuve
Bijuve simplifies hormone therapy for women with a uterus into one daily capsule instead of two separate prescriptions. Because it is taken orally, it carries the higher clotting risk associated with oral versus transdermal estrogen, and it is not an option for women without a uterus. There is no generic version, and its list price runs well above generic estradiol patch pricing.
Pros
One capsule combines estrogen and progesterone, no second prescription
No patch or skin site care required
Only FDA-approved bioidentical estradiol and progesterone combo capsule
Cons
Oral estrogen carries higher clot risk than transdermal options
Not approved for women without a uterus
No generic version, costing roughly $257 to $351 a month
Not approved for preventing osteoporosis
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.